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Objectives
Health-related quality of life (HRQL) is modulated by the type and frequency of symptoms experienced in daily life. Such a relationship is likely determined in
part by treatment regimen and health care system. We studied how symptoms reported by HIV patients under PI- vs. NNTI-based HAART relate to diﬀerent HRQL
dimensions on the PROQOL-HIV questionnaire.
Methods
N = 424HAART patients (4110 yrs., 36% females, 8 countries: USA, Australia, France, Senegal, China, Thailand, Cambodia,
Brazil), without comorbidity, completed a 31-symptomHIV checklist (presence/absence) and the PROQOL-HIV questionnaire.
Hierarchical cluster analysis helped to study the structure of symptoms experienced in patients under PI (N = 242) or NNTI
(N = 182) regimen. Canonical correlation analysis (CCA) was used to uncover the relationships between symptoms and
HRQL dimensions, and between-country variations.
The PROQOL-HIV questionnaire includes 43 items covering eight dimensions: Physical Health and Symptoms (PHS, 9 items),
Treatment Impact (TI, 10), Emotional Distress (ED, 4), Health Concerns (HC, 4), Body Change (BC, 4), Intimate Relationships
(IR, 3), Social Relationships (SR, 2), Stigma (ST, 2). It has been shown to meet standard psychometric criteria (Duracinsky et
al. JAIDS, submitted).
Results
Hierarchical cluster analysis showed that a common group of symptoms
related to body fat (lipodystrophy) and weight changes was shared by pa-
tients across treatment regimens (see 3rd cluster for the NNTI group and
last cluster for the PI group, starting from the left in Fig. A). The num-
ber of clusters was selected by looking at the resulting dendrogram, but






























































































































































































































































































































































































































Figure A. Cluster results






of fat loss were found
to occur together in both
groups.
The frequency of some side-eﬀects—sleep disturbance, headache, diar-
rhea, nausea, fatigue and pain—was higher with PI regimens (Fig. B),
while speciﬁc patterns of symptoms associations were found in both
groups (Fig. C).
Figure B. Mean frequency of
symptoms in the two treat-
ment groups.
For example, nausea is more
prevalent within the PI group;
thinness of buttocks is more
often found with NNTI.
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The CCA seeks maximally correlated principal directions in two-block
data. It showed that (a) the following symptoms: body fat change, sleep
disturbance, skin problems and abdominal pain were related to the ‘body
change’ and ‘physical health and symptoms’ HRQL dimensions (canoni-
cal correlation, 0.78), and (b) symptoms concerning physical appearance
were related to the ‘stigma’ dimension, but not other side-eﬀects (Fig. D).
Figure C.
Co-occurence of symptoms. Darker color indicate a
stronger association (as measured by observed fre-
quency) between symptoms.
For example, muscular pain generally comes with fa-
tigue, and fatigue is often found occuring together
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This study also replicated a common ﬁnding whereby patients from
Western countries (France, Australia, USA) tend to report better HRQL
compared to Chinese and Cambodian patients, the latter also experienc-
ing more symptoms due to PI-based treatment.
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CCA biplot for symptoms
(left) and HRQL (right).
Longer arrows indicate
a higher contribution,
while small angles be-




Treatment-related symptoms alignedwith PROQOL-HIV dimensions and known diﬀerences between countries. The use of CCA as an exploratorymultiple endpoints
model helped to unravel complex relationships between symptoms and HRQL facets. The choice of treatment strategies should rely not only on symptoms
experience, but also account for their relations to HRQL in light of varying access to care.
